Log in
NYSE:PBH

Prestige Consumer Healthcare Stock Forecast, Price & News

$34.55
+0.01 (+0.03 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$34.20
Now: $34.55▼
$35.00
50-Day Range
$34.54
MA: $37.11▼
$40.79
52-Week Range
$27.40
Now: $34.55▼
$46.12
Volume521,117 shs
Average Volume474,352 shs
Market Capitalization$1.73 billion
P/E Ratio11.56
Dividend YieldN/A
Beta0.77
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning. The company's OTC healthcare products include BC/Goody's analgesic powders, Beano for gas prevention, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids/lozenges, Clear Eyes for eye allergy/redness relief, Compound W for wart removal, Debrox for ear wax removal, DenTek PEG oral care, Dramamine for motion sickness relief, and Efferdent denture cleanser tablets. Its OTC healthcare products portfolio also comprises Fess nasal saline spray, Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Hydralyte for oral rehydration, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Pedia-Lax pediatric laxatives, Summer's Eve for feminine hygiene, Little Remedies pediatric OTC products, and The Doctor's NightGuard dental protectors. In addition, the company offers household cleaning products, such as abrasive tub and tile cleaners under the Comet name, as well as Chore Boy, and Spic and Span names. It serves mass merchandisers; and drug, food, dollar, convenience, and club stores. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Read More
Prestige Consumer Healthcare logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.55 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPersonal Products
SectorConsumer Discretionary
Current SymbolNYSE:PBH
Previous Symbol
CUSIP74112D10
CIK1295947
Webwww.prestigebrands.com
Phone914-524-6800

Debt

Debt-to-Equity Ratio1.32
Current Ratio2.24
Quick Ratio1.35

Price-To-Earnings

Trailing P/E Ratio11.56
Forward P/E Ratio10.97
P/E Growth2.9

Sales & Book Value

Annual Sales$963.01 million
Price / Sales1.80
Cash Flow$3.47 per share
Price / Cash Flow9.97
Book Value$23.30 per share
Price / Book1.48

Profitability

EPS (Most Recent Fiscal Year)$2.96
Net Income$142.28 million
Net Margins15.84%
Return on Equity13.81%
Return on Assets4.64%

Miscellaneous

Employees530
Outstanding Shares50,189,000
Market Cap$1.73 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$34.55
+0.01 (+0.03 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PBH News and Ratings via Email

Sign-up to receive the latest news and ratings for PBH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Prestige Consumer Healthcare (NYSE:PBH) Frequently Asked Questions

How has Prestige Consumer Healthcare's stock price been impacted by Coronavirus?

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PBH stock has decreased by 3.8% and is now trading at $34.55.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Prestige Consumer Healthcare?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Prestige Consumer Healthcare.

When is Prestige Consumer Healthcare's next earnings date?

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Prestige Consumer Healthcare.

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc (NYSE:PBH) announced its quarterly earnings results on Thursday, August, 6th. The company reported $0.86 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.70 by $0.16. The business had revenue of $229.40 million for the quarter, compared to analyst estimates of $221.27 million. Prestige Consumer Healthcare had a return on equity of 13.81% and a net margin of 15.84%. The business's revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.65 EPS.
View Prestige Consumer Healthcare's earnings history.

What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?

Prestige Consumer Healthcare updated its second quarter earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of $0.70 or more for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.71. The company issued revenue guidance of $225 million or more, compared to the consensus revenue estimate of $236.06 million.

What price target have analysts set for PBH?

7 Wall Street analysts have issued twelve-month price objectives for Prestige Consumer Healthcare's shares. Their forecasts range from $43.00 to $97.00. On average, they expect Prestige Consumer Healthcare's stock price to reach $69.00 in the next twelve months. This suggests a possible upside of 99.7% from the stock's current price.
View analysts' price targets for Prestige Consumer Healthcare.

Who are some of Prestige Consumer Healthcare's key competitors?

Some companies that are related to Prestige Consumer Healthcare include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Medifast (MED), USANA Health Sciences (USNA), Inter Parfums (IPAR), Revlon (REV), Nature's Sunshine Products (NATR) and Veru (VERU).
View all competitors.

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), Wells Fargo & Company (WFC), IBM (IBM), Micron Technology (MU), ONEOK (OKE) and Teva Pharmaceutical Industries (TEVA).

Who are Prestige Consumer Healthcare's key executives?

Prestige Consumer Healthcare's management team includes the following people:
  • Mr. Ronald M. Lombardi, Chairman, Pres & CEO (Age 55)
  • Ms. Christine Sacco, Chief Financial Officer (Age 43)
  • Mr. William C. P'Pool, Sr. VP, Gen. Counsel & Corp. Sec. (Age 54)
  • Mr. Timothy J. Connors, Exec. VP of Sales & Marketing (Age 52)
  • Mr. Jeff Zerillo, Sr. VP of Operations

What is Prestige Consumer Healthcare's stock symbol?

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.93%), Macquarie Group Ltd. (3.54%), FMR LLC (2.37%), Goldman Sachs Group Inc. (2.23%), Nuveen Asset Management LLC (2.00%) and Fisher Asset Management LLC (1.58%). Company insiders that own Prestige Consumer Healthcare stock include Paton Brett, Ronald M Lombardi and Timothy Connors.
View institutional ownership trends for Prestige Consumer Healthcare.

Which institutional investors are selling Prestige Consumer Healthcare stock?

PBH stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Goldman Sachs Group Inc., NN Investment Partners Holdings N.V., Vanguard Group Inc., NN Investment Partners Holdings N.V., Bank of America Corp DE, Dalton Greiner Hartman Maher & Co., and Skyline Asset Management LP.
View insider buying and selling activity for Prestige Consumer Healthcare.

Which institutional investors are buying Prestige Consumer Healthcare stock?

PBH stock was acquired by a variety of institutional investors in the last quarter, including Glenmede Trust Co. NA, AQR Capital Management LLC, Prudential Financial Inc., Nordea Investment Management AB, UBS Group AG, Macquarie Group Ltd., Canada Pension Plan Investment Board, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for Prestige Consumer Healthcare.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Prestige Consumer Healthcare's stock price today?

One share of PBH stock can currently be purchased for approximately $34.55.

How big of a company is Prestige Consumer Healthcare?

Prestige Consumer Healthcare has a market capitalization of $1.73 billion and generates $963.01 million in revenue each year. The company earns $142.28 million in net income (profit) each year or $2.96 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe.

What is Prestige Consumer Healthcare's official website?

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

How can I contact Prestige Consumer Healthcare?

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.